COVID-19 Antivirals Pregnancy Registry

In collaboration with all UK Health Departments and the Medicines and Healthcare products Regulatory Agency (MHRA), UKTIS are monitoring the safety of new COVID-19 antivirals when taken in or around pregnancy.

(Please note: For simplicity and clarity, on this page, we use the term "pregnant women" as a general term to refer to anyone who is pregnant. UKTIS acknowledge that not all people who are pregnant and give birth identify as women, and it is important that evidence-based care for maternity, perinatal and postnatal health is inclusive. We are committed to equality in society, and no person should feel excluded from our services or information.)

Who can report to the registry?

  • Healthcare professionals
  • Pregnant women
  • Partners of pregnant women
    • If you live in the UK and (1) you have a patient that has used a COVID-19 antiviral medication when they were pregnant or shortly before pregnancy, or (2) if you used a COVID-19 antiviral medication when you were pregnant, or (3) if you used a COVID-19 antiviral medication around the time your partner conceived, please report the pregnancy to UKTIS today.

      To report a pregnancy to UKTIS, please contact us by telephone (0344 892 0909, available 9am to 5pm, Monday to Friday excluding bank holidays).

      How does the registry work?

      - Healthcare professionals and pregnant women/partners of pregnant women in England, Scotland and Wales can report pregnant women or the partners of pregnant women who used COVID-19 antivirals either during pregnancy or around the time of conception to UKTIS. This reporting does not require consent from the patient (England and Wales - Section 251 Exemption - PHE CAP approval number 13091, Scotland - approval pending). Reported pregnancies are subsequently followed-up using standardised procedures

      - Healthcare professionals in Northern Ireland cannot currently report pregnant women to the registry. However, pregnant women and partners of pregnant women who have used COVID-19 antivirals during pregnancy or around the time of conception can self-report their pregnancy to UKTIS.

      For more information about how the registry works, see here.

      To report a pregnancy to UKTIS, please contact us by telephone (0344 892 0909, available 9am to 5pm, Monday to Friday excluding bank holidays).

      Information about the safety of COVID-19 antivirals

      If you are looking for information about the safety of COVID-19 antivirals, please see our information sources below:

      Summary Information for Healthcare Professionals:

      - Molnupiravir (manufacturer information: Lagevrio)

      - Paxlovid (nirmatrelvir/ritonavir - see COVID-19 antivirals section)

      Summary Information for Patients:

      - Molnupiravir (manufacturer information: Lagevrio)

      Information about COVID-19 antiviral clinical trials

      - PANORAMIC trial

      My bump’s record

      Create your own ‘My bump’s record’.

      Provide information about your pregnancy to help women in the future.

      Login to my bumps

      Join my bumps